StockNews.com Initiates Coverage on Curis (NASDAQ:CRIS)

Analysts at StockNews.com began coverage on shares of Curis (NASDAQ:CRIS) in a research note issued to investors on Friday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Curis in a research note on Tuesday, December 10th.

Curis Stock Performance

Shares of CRIS opened at $2.66 on Friday. The stock has a 50-day moving average of $3.12 and a two-hundred day moving average of $3.98. Curis has a one year low of $2.57 and a one year high of $17.49. The stock has a market cap of $22.52 million, a P/E ratio of -0.34 and a beta of 3.49.

Institutional Investors Weigh In On Curis

Several large investors have recently bought and sold shares of CRIS. Focused Wealth Management Inc increased its stake in Curis by 9.5% during the 4th quarter. Focused Wealth Management Inc now owns 59,204 shares of the biotechnology company’s stock worth $181,000 after buying an additional 5,138 shares in the last quarter. CM Management LLC increased its stake in Curis by 83.3% during the 4th quarter. CM Management LLC now owns 220,000 shares of the biotechnology company’s stock worth $673,000 after buying an additional 100,000 shares in the last quarter. Geode Capital Management LLC increased its stake in Curis by 27.3% during the 4th quarter. Geode Capital Management LLC now owns 83,129 shares of the biotechnology company’s stock worth $254,000 after buying an additional 17,820 shares in the last quarter. M28 Capital Management LP raised its holdings in shares of Curis by 23.5% during the 4th quarter. M28 Capital Management LP now owns 521,059 shares of the biotechnology company’s stock worth $1,594,000 after acquiring an additional 99,108 shares during the period. Finally, Samsara BioCapital LLC acquired a new position in shares of Curis during the 4th quarter valued at about $607,000. 29.97% of the stock is currently owned by hedge funds and other institutional investors.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.